A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma

ConclusionsOur work highlighted PD-L2 as a promising immunotherapeutic target with prognostic value combined with complex tumor infiltrating cells in PDAC.

Source: Journal for Immunotherapy of Cancer - August 28, 2019 Category: Cancer & Oncology Source Type: research